In tyrosine kinase inhibitors (TKIs)-resistant small cell lung cancer cell lines, AMF-26 induced downregulation of MET, which is also known as hepatocyte growth factor receptor, suggesting that anticancer mechanism of AMF-26 was different from that of known EGFR-TKIs. The gene discussed is MET; the disease is small cell lung carcinoma.